Update on morphea: Part II. Outcome measures and treatment

Nicole Fett, Victoria P. Werth

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.

Original languageEnglish (US)
Pages (from-to)231-242
Number of pages12
JournalJournal of the American Academy of Dermatology
Volume64
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Localized Scleroderma
Outcome Assessment (Health Care)
Skin
Methotrexate
Collagen
Steroids
Equipment and Supplies

Keywords

  • autoimmune connective tissue disorder
  • fibrosing disorders
  • localized scleroderma
  • morphea
  • scleroderma
  • systemic sclerosis

ASJC Scopus subject areas

  • Dermatology

Cite this

Update on morphea : Part II. Outcome measures and treatment. / Fett, Nicole; Werth, Victoria P.

In: Journal of the American Academy of Dermatology, Vol. 64, No. 2, 02.2011, p. 231-242.

Research output: Contribution to journalArticle

@article{4e81fa684a974e999e22620d6f2bb883,
title = "Update on morphea: Part II. Outcome measures and treatment",
abstract = "Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.",
keywords = "autoimmune connective tissue disorder, fibrosing disorders, localized scleroderma, morphea, scleroderma, systemic sclerosis",
author = "Nicole Fett and Werth, {Victoria P.}",
year = "2011",
month = "2",
doi = "10.1016/j.jaad.2010.05.046",
language = "English (US)",
volume = "64",
pages = "231--242",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Update on morphea

T2 - Part II. Outcome measures and treatment

AU - Fett, Nicole

AU - Werth, Victoria P.

PY - 2011/2

Y1 - 2011/2

N2 - Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.

AB - Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.

KW - autoimmune connective tissue disorder

KW - fibrosing disorders

KW - localized scleroderma

KW - morphea

KW - scleroderma

KW - systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=78751507136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751507136&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.05.046

DO - 10.1016/j.jaad.2010.05.046

M3 - Article

C2 - 21238824

AN - SCOPUS:78751507136

VL - 64

SP - 231

EP - 242

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -